International Stem Cell (ISCO) has announced that it’s wholly owned subsidiary Lifeline Skin Care and its new stem cell skin care line has exceeded sales expectations since its trial launch at the tail end of last year. Lifeline carried out the evaluation of the product line in November and December 2010, and with the results, will now look to move forward with its general marketing program. "Sales to date have greatly exceeded our expectations for the trial launch,” said Dr. Ruslan Semechkin, CEO of Lifeline Skin Care. He explained that the initial sales resulted from a very limited product offering made to subscribers of only one of the several newsletters sent out, plus a small direct mailing to interested parties and ISCO's shareholders who had signed up for general corporate information through the website.
Parthenogenetic stem cell extract
Lifeline Skin Care products contain parthenogenetic stem cell extract and were developed by the ISCO research team in collaboration with cosmetic chemists. The company claims the breakthrough products deliver leading advances in skin rejuvenation technology that helped to prevent and repair damaged skin.
Thanks to the evaluation results, the California-based firm says it is now ready to move forward to the next phase of distribution, which will commence near the end of March. That phase will consist initially of a customer solicitation conducted by its marketing partner, John Mauldin's specialty internet and direct response marketing organization. "We almost never endorse or sell a retail product," said Mr. Mauldin, "but the results of both our informal testing and the company's formal studies have convinced us that the Lifeline Skin Care products really are a game-changing advance in skin care. I have not seen such a strong response in online marketing in the last ten years. We are all very excited and proud to be involved," he added.
First to incorporate stem cell
The Lifetime Skin Care line went on sale in the U.S., and was thought to be one of the first anti-aging lines to incorporate stem cell technology. The launch included two products, consisting of a defensive Day Moisture Serum, and Recovery Night Moisture Serum, which was distributed at select retail outlets in the US as well as online. Following the results however, Kenneth Aldrich, Chairman of ISCO, did issue a cautionary comment to its investors.
"We are incredibly excited by the prospects of this new product from our Lifeline Skin Care subsidiary. Selling over 7,000 bottles through a very limited trial launch, as we have done, represents a significant first step, but it would be imprudent for us to base projections of future sales or profits on a sample base of this size."
Parthenogenetic stem cell extract
Lifeline Skin Care products contain parthenogenetic stem cell extract and were developed by the ISCO research team in collaboration with cosmetic chemists. The company claims the breakthrough products deliver leading advances in skin rejuvenation technology that helped to prevent and repair damaged skin.
Thanks to the evaluation results, the California-based firm says it is now ready to move forward to the next phase of distribution, which will commence near the end of March. That phase will consist initially of a customer solicitation conducted by its marketing partner, John Mauldin's specialty internet and direct response marketing organization. "We almost never endorse or sell a retail product," said Mr. Mauldin, "but the results of both our informal testing and the company's formal studies have convinced us that the Lifeline Skin Care products really are a game-changing advance in skin care. I have not seen such a strong response in online marketing in the last ten years. We are all very excited and proud to be involved," he added.
First to incorporate stem cell
The Lifetime Skin Care line went on sale in the U.S., and was thought to be one of the first anti-aging lines to incorporate stem cell technology. The launch included two products, consisting of a defensive Day Moisture Serum, and Recovery Night Moisture Serum, which was distributed at select retail outlets in the US as well as online. Following the results however, Kenneth Aldrich, Chairman of ISCO, did issue a cautionary comment to its investors.
"We are incredibly excited by the prospects of this new product from our Lifeline Skin Care subsidiary. Selling over 7,000 bottles through a very limited trial launch, as we have done, represents a significant first step, but it would be imprudent for us to base projections of future sales or profits on a sample base of this size."
